ACT Brief: Diversity Built Into Trial Design, AI Impact Across Trial Lifecycle, and Companion Diagnostics Adoption

Apr 09, 10:00 AM
Headliner
Share
Subscribe
In today's ACT Brief, we explore why clinical trial diversity requires protocol redesign from the outset, the highest-impact opportunities for AI across the complete trial lifecycle, and the regulatory and operational barriers slowing companion diagnostic adoption in oncology.
Share
Subscribe
Next
ACT Brief: Governance vs. Execution in Pharma Modernization, AI Workforce Augmentation Planning, and Adaptive Trial Regulatory Shifts
Top episodes
AI in Clinical Trials - A Long, But Promising Road Ahead
by Applied Clinical Trials
Unifying Industry to Better Understand GCP Guidance
by Applied Clinical Trials
Diversity in Clinical Trials: The Need to Take Action
by Applied Clinical Trials